Medcan News

19th of February 2019

Medcan Looking for new Investors – Press Release FEB 2019.1 (003)

Medcan Australia opens doors to new investment:

The board of Medcan Australia are interested in speaking to investors, both locally and internationally,
who are looking to enter the Australian and International Medicinal Cannabis Industry and partner with
one of the leading Australian companies in this space.

Medcan Australia is one of only a few companies in Australia to hold the full suite of ODC (Office
of Drug Control) Licences/State Licences & DAWR Permit being:
1) Cultivation and Production Licence
2) Manufacture Licence
3) Import Licence
4) Export Licence
5) DAWR Permit
6) QLD Health Licence

Medcan Australia currently have a DA (Council) approved facility, being a secure industrial building, with
the capacity to produce up to 6500kgs of dried flower per annum. This state of the art facility utilizes the
latest LED technology, vertical racking system and fully automated climate control system to produce the
highest quality products.

Medcan Australia have secured a number of offtake agreements and supply agreements with both local
and international parties. Medcan Australia have also signed a number of Contract Manufacturing Agreements with other Australia LP’s, to contract manufacture their dried flower and full extract oils under Medcan’s manufacturing capabilities and licences.

Background:
Medcan Australia Pty Ltd was founded in 2016 and was one of the first Australian companies to be licensed by the ODC (Office of Drug Control) to cultivate, produce, manufacture, import and export Medicinal Cannabis products.

The company was founded with a single vision to provide patients with a high quality, fair priced medicinal cannabis product.

Medcan Australia is positioned to be a front runner in the Australia Medicinal Cannabis Industry with a
completely vertically integrated model. Medcan Australia will cultivate, produce and manufacture high
quality Medicinal Cannabis products for clinical trials, individual patient access and international export.
Using automated indoor cultivation processes designed to ensure consistent results, Medcan Australia
aims to assure consumers of the quality, composition and reliability of their supply.

Comments from Craig Cochran – CEO Medcan Australia Pty Ltd: Medcan Australia Pty Ltd Founder & CEO, Craig Cochran said: “We are excited to now be able to open discussions with both local and international interested parties.” Craig continued: “We are in the unique position of being one of only a handful of Australian companies that have secured all of the ODC licence requirements for a completely vertically integrated business model. We have also executed a number of commercial supply agreements and LOI’s allowing for significant revenue once fit out of our state of the art facility is complete in early 2019”

Medcan Australia will be producing a range of high quality Medicinal Cannabis strains with varying CBD –
THC profiles to suit varying medicinal applications, with all of our products manufactured to GMP
certification, ensuring consistent medicine for patients.

For Further Information, or to obtain an Investor Presentation, please contact:
Craig Cochran – CEO Medcan Australia
+61407597023
Po Box 4579, Springfield, QLD, Australia, 4300
craig@medcanaustralia.com.au
www.medcanaustralia.com.au